Introduction
A purine nucleoside analog, 2-chlorodeoxyadenosine (2-CdA) has been proved to be effective in a variety of lymphoid malignancies, including not only those of B-cell origin but also of T-cell origin (1, 2) . However, there are no clinical data available as to whether this agent is also effective against adult T-cell leukemia-lymphoma (ATL), which has a poor prognosis despite various combination chemotherapies (3) (4) (5) . Here, we report effective treatment with 2-CdAin a patient with ATL, shown in a part of the results of a cooperative phase I study in Japan.
Case Report
A 72-year-old Japanese male was diagnosed as having acute-type ATLin October 1994. The diagnosis was confirmed by positive serum human T-cell leukemia virus type I (HTLV-I) antibodies (x8,192) and by monoclonal integration of the HTLV-I proviral DNAin the peripheral blood mononuclear cells. He was first treated for about eight months with MST-16 [4,4' -( 1 ,2-ethanediyl) bis ( 1 -isobutoxycarbonyloxymethyl-2,6- dioxopiperazine)], an orally administered bis (2,6- dioxopiperazine) analog and an inhibitor of topoisomerase II (6) , because a phase II study showed that MST-16produced a 59% complete remission (CR) and partial remission (PR) in 17 previously untreated patients with ATLin Japan (7). Wegave MST-16orally for five consecutive days every three weeks in the daily dose of 1,600 mg in the first four courses and then 2,400 mgin the subsequent seven courses. After initial seven courses, a minor response was observed. However, he gradually became refractory to this drug. He was hospitalized because of the deterioration of leukocytosis ( 196.9xlO9// with 90%ATLcells) and generalized lymphadenopathy (the largest lymph node measured 5.2x2.8 cm in the right axilla) with bone marrow invasion of ATL cells (51.2%). No hepatosplenomegaly was seen. His hemoglobin concentration (13.0 g/dl) and platelet count (230xl09//) were normal. The serum lactate dehydrogenase (LDH) and soluble interleukin-2 (IL-2) receptor (SIL-2R) levels were 3,240 IU/Z and 8 1,400 U/ml, respectively. There was no hypercalcemia (9.4 mg/dl). The patient was eligible for a phase I clinical study of2-CdA (8) in which 2-CdA was administered as a continuous infusion in a daily dose of 0.09 mg/kg over 7 days, starting on August 8th, 1995, three weeks after the last administration ofMST-16. lymphadenopathy was reduced to 4%with the sum of the products (the right axillary lymph node measured 1.0x0.4 cm), serum LDHlevel returned to normal (281 IU//), SIL-2R level decreased to 2, 150 U/ml. No significant adverse drug reactions occurred. In April 1996, a relapse was noted with the appearance of skin rash and new lymph node swelling in the right inguinal region. The duration of partial remission was 10 weeks (Fig.1) .
Discussion 2-CdA is highly effective forB-cell malignancies, especially for hairy cell leukemia (9). It may also be effective for T-cell malignancies, because, in vitro, T cells are more vulnerable thanB cells tothe actionof2-CdA (10). O'Brienetal (2) treated 22 patients with T-cell malignancies with 2-CdA administered as a continuous infusion in a daily dose of4 mg/m2over7 days. Nine patients (41%) responded including four with CR. They concluded that 2-CdA is an effective therapy for some T-cell malignancies and it deserves wider evaluation in this subset of patients. Their results, coupled with the observations that another purine deoxynucleoside analogue, 2'-deoxycoformycin, was an effective agent against ATL(ll-13), prompted us to investigate whether 2-CdA showed activity in ATL, a T-cell malignancy caused by HTLV-I (14) and generally resistant to cytotoxic chemotherapy (3) (4) (5) . In our patient with an acute type ofATLwhohad been given 1 1 courses ofMST-16and had become resistant to this drug, 2-CdAled to a partial response that was apparently biphasic (Fig.  1) . The first phase was after the first course of2-CdAin which a rapid decrease of peripheral blood ATLcells and a shrinkage of lymphadenopathywere observed. After the second course, slight deterioration was noted. A more lasting effect, including a decrease in bone marrow ATLcells, followed the third course, that is the second phase. ATLcells in the peripheral blood completely disappeared eight months after the start of the 2-CdAtherapy. Suppression of CD4+lymphocyte counts (decreased ratio of CD4+/CD8+)persisted, thereafter, until a relapse (Table 1) . Interestingly, down-regulation of CD25 on peripheral blood ATLcells was already noted in the first phase (day 28) ( Table 1 ). These findings provide some insight into the mechanism of the action of 2-CdAon ATLbecause CD25has an important role in the proliferation of ATLcells (15) Figure 1 . Clinical course. *E erythroid cells; 2G granulocytes; (The area between G and ATLcells represents normal bone marrow cells other than erythroid cells and granulocytes); 3Lymphadenopathyis represented by the sum of the products of all the lymph nodes palpable; 4sIL-2R soluble interleukin-2 receptor. Our results suggest that 2-CdAmaybe an effective agent for patients with ATLand warrants further studies. A multicenter phase II study of 2-CdA is ongoing in Japan.
